• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Belite Bio Inc

    2/15/23 1:36:20 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLTE alert in real time by email
    SC 13G 1 tm236985d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934*

     

    Belite Bio, Inc
    (Name of Issuer)
     
    Ordinary shares, par value US$0.0001 per share
    (Title of Class of Securities)
     
    07782B 104**
    (CUSIP Number)
     
    December 31, 2022
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    ¨Rule 13d-1(c)
    xRule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    ** There is no CUSIP number assigned to the ordinary shares of the Issuer (“Ordinary Shares”). CUSIP number 07782B 104 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on NASDAQ Capital Market under the symbol “BLTE”. Each ADS represents one Ordinary Share.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 07782B 104SCHEDULE 13GPage 2 of 4 Pages

     

    1

    NAMES OF REPORTING PERSONS

     

    Yu-Hsin Lin

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ¨

    (b)  ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Australia

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY

     

    EACH

     

    REPORTING

     

    PERSON WITH

    5

    SOLE VOTING POWER

     

    2,485,308

     

    6

    SHARED VOTING POWER

     

     

    7

    SOLE DISPOSITIVE POWER

     

    2,485,308

     

    8

    SHARED DISPOSITIVE POWER

     

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,485,308(1)

     

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

     

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.97%(2)

     

    12

    TYPE OF REPORTING PERSON

     

    IN

     

           

     

     

    (1)Include (i) 731,728 Ordinary Shares directly held by Yu-Hsin Lin; (ii) 22,777 Ordinary Shares underlying share options granted to Yu-Hsin Lin that are vested or will be vested within 60 days of December 31, 2022; and (iii) 1,730,803 Ordinary Shares indirectly held by Yu-Hsin Lin through Lin Bioscience International Ltd., which is our principal shareholder and the wholly-owned subsidiary of our controlling shareholder Lin BioScience, Inc.(stock code: 6696.TW).
    (2)The percentage is calculated based upon an aggregate of (i) 24,898,908 Ordinary Shares outstanding as of December 31, 2022 as provided by the Issuer; and (ii) 22,777 Ordinary Shares underlying share options granted to Yu-Hsin Lin that are vested or will be vested within 60 days of December 31, 2022.

     

     

     

     

    CUSIP No. 07782B 104SCHEDULE 13GPage 3 of 4 Pages

     

    Item 1(a)Name of Issuer:

     

    Belite Bio, Inc (the “Issuer”)

     

    Item 1(b)Address of Issuer’s Principal Executive Offices:

     

    5820 Oberlin Drive, Suite 101,

    San Diego, CA 92121

    United States of America

     

    Item 2(a)Name of Persons Filing:

     

    This Schedule 13G is filed on behalf of Yu-Hsin Lin (“Reporting Person”)

     

    Item 2(b)Address of Principal Business Office or, If None, Residence

     

    The business address of the Reporting Person is 36F., No. 68, Sec. 5, Zhongxiao E. Rd., Xinyi Dist., Taipei City 110, Taiwan

     

    Item 2(c)Citizenship

     

    Yu-Hsin Lin is a citizen of Australia

     

    Item 2(d)Title of Class of Securities:

     

    Ordinary Shares, par value $0.0001 per share

     

    Item 2(e)CUSIP Number:

     

    07782B 104

     

    Item 3.Statement Filed Pursuant to Rule 13d-1(b) or 13d-2(b) or (c):

     

    Not applicable.

     

    Item 4.Ownership

     

    The information for the Reporting Person contained in rows 5-11 of the cover page and Item 2(a) is incorporated herein by reference.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6.Ownership of More Than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certifications

     

    Not applicable.

     

     

     

     

    CUSIP No. 07782B 104SCHEDULE 13GPage 4 of 4 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 15, 2023  
       
      Yu-Hsin Lin
       
      By: /s/Yu-Hsin Lin
      Name: Yu-Hsin Lin
      Title: Chief Executive Officer and Chairman

     

     

     

    Get the next $BLTE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLTE

    DatePrice TargetRatingAnalyst
    12/14/2023$60.00Buy
    Maxim Group
    7/28/2023$43.00Overweight
    Cantor Fitzgerald
    7/26/2023$25.00Outperform
    SVB Securities
    8/1/2022$58.00Buy
    H.C. Wainwright
    More analyst ratings

    $BLTE
    SEC Filings

    View All

    SEC Form F-3ASR filed by Belite Bio Inc

    F-3ASR - BELITE BIO, INC (0001889109) (Filer)

    10/22/25 8:00:49 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Belite Bio Inc

    144 - BELITE BIO, INC (0001889109) (Subject)

    10/14/25 3:05:20 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Belite Bio Inc

    6-K - BELITE BIO, INC (0001889109) (Filer)

    9/8/25 8:00:21 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Belite Bio with a new price target

    Maxim Group initiated coverage of Belite Bio with a rating of Buy and set a new price target of $60.00

    12/14/23 8:06:18 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Belite Bio with a new price target

    Cantor Fitzgerald initiated coverage of Belite Bio with a rating of Overweight and set a new price target of $43.00

    7/28/23 7:14:28 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Securities initiated coverage on Belite Bio with a new price target

    SVB Securities initiated coverage of Belite Bio with a rating of Outperform and set a new price target of $25.00

    7/26/23 7:15:36 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results

    SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, November 10, 2025, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update for the third quarter ended September 30, 2025. Webcast InformationDate: Monday, November 10, 2025Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)Webcast Link: https://events.q4inc.com/attendee/847711723 Webcast Link InstructionsYou can join the live webcast by visiting the li

    11/3/25 8:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio Announces UK's Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

    MHRA response is based on the Phase 3 DRAGON interim analysis results Topline final data expected in Q4 2025 SAN DIEGO, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ:BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has agreed to accept a Conditional Marketing Authorization application for Tinlarebant for the treatment of Stargardt disease based on the interim analysis results from the Phase 3 DRAGON trial. "We are extremely pleased with the outcome of our eng

    11/2/25 9:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CORRECTION -- International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 04, 2025

    NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- In a release issued yesterday October 30, 2025 by Virtual Investor Conferences, please note several agenda items were modified. The corrected release follows: Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Tuesday, November 04, 2025, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the U.S. Representatives from participating companies based in Australia, China, Hong Kong, Germany, Spain, Sweden, and the Cayman Islands will respond to questions during formal presentations. The conference is targeted to all categories

    10/31/25 8:35:00 AM ET
    $BLTE
    $COE
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Consumer Services
    Real Estate

    $BLTE
    Leadership Updates

    Live Leadership Updates

    View All

    Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

    Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its board of directors has appointed Hendrik P. N. Scholl, MD, MA, as the Chief Medical Officer of the Company, effective immediately. Dr. Scholl is the foremost globally recognized authority on Stargar

    9/1/24 8:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Belite Bio Inc

    SC 13G - BELITE BIO, INC (0001889109) (Subject)

    2/12/24 9:08:25 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Belite Bio Inc

    SC 13G - BELITE BIO, INC (0001889109) (Subject)

    2/12/24 8:40:46 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Belite Bio Inc

    SC 13G - BELITE BIO, INC (0001889109) (Subject)

    2/15/23 1:36:20 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    Financials

    Live finance-specific insights

    View All

    Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

    Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1)Pivotal global Phase 3 PHOENIX trial of Tinlarebant in geographic atrophy (GA) subjects is ongoing with more than 280 subjects enrolledAppointed Hendrik P.N. Scholl, MD, MA, a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest natural history study of Stargardt disease, as Chief Medical OfficerInterim analysis from the pivotal global Phase 3 DRAGON trial of Tinlarebant in adolescent STGD1 subjects anticipated by end of 2024 or early 2025Company to host webcast on Tuesday, November 12, 2024, at 4:30 p.m. EST SAN DIEGO,

    11/12/24 1:00:25 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

    Completed enrollment in pivotal Phase 3 "DRAGON" trial for Tinlarebant in adolescent Stargardt disease ("STGD1") with 104 subjects enrolled across 11 countries worldwideFirst subject dosed with Tinlarebant in pivotal global Phase 3 "PHOENIX" trial in Geographic Atrophy ("GA")Oral, once-daily Tinlarebant continues to be safe and well tolerated, slowing expansion of autofluorescence, reducing incident atrophic retinal lesion growth rate, and stabilizing visual acuity up to 24-months in Phase 2 STGD1 trial ("LBS-008-CT02")Interim Phase 3 safety and efficacy data from pivotal "DRAGON" trial expected in 2H 2024Conference Call and Webcast Tuesday, November 14, 2023, at 4:30 p.m. ET

    11/13/23 8:15:47 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results

    In 18-month interim data from ongoing 2-year, Phase 2 Stargardt disease ("STGD1") trial ("LBS-008-CT02"), we continued to observe that oral Tinlarebant is safe and well tolerated in adolescent STGD1 subjectsA continued trend of slowing expansion of autofluorescence was observed and the growth rate of incident atrophic retinal lesions was reduced with Tinlarebant in LBS-008-CT02 compared to a natural history study of the disease ("ProgStar")Stabilization of visual acuity with no significant loss and no clinically significant changes in retinal thickness observed over 18 months of treatment with Tinlarebant in LBS-008-CT0258 subjects have been enrolled in the pivotal Phase 3 "DRAGON" trial eva

    5/10/23 7:58:59 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care